Brian J. Blaser is the President and CEO of QuidelOrtho Corporation, where he has been steering the ship since May 2024. He has a strong background in the medical field, previously serving as Executive Vice President at Abbott Laboratories, leading...

Brian J. Blaser is the President and CEO of QuidelOrtho Corporation, where he has been steering the ship since May 2024. He has a strong background in the medical field, previously serving as Executive Vice President at Abbott Laboratories, leading their global diagnostics operations for over seven years. Brian has also held key positions at companies like Johnson & Johnson and Eastman Kodak, giving him a broad understanding of healthcare and diagnostics. He holds a mechanical engineering degree from the University of Dayton and an MBA from the Rochester Institute of Technology. Beyond his leadership roles, Brian has been an advisor to investment firms and served on various boards, showing he's not just about profit but also about shaping the industry. In 2023, he earned a total compensation of around $3.32 million, reflecting his performance-based structure, which includes a solid salary and stock options tied to company success. With a solid education and experience, Brian is well-equipped to lead QuidelOrtho in its next chapter.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other QuidelOrtho Corporation CEOs

Q

Brian J. Blaser

CEO of QuidelOrtho Corporation

Sector of Economy

Healthcare

CEO of QuidelOrtho Corporation for

1 year 0 months (May 2024 - Present)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Brian J. Blaser

Holdings

See how much did Brian J. Blaser make over time.

Brian J. Blaser's financial stake in QuidelOrtho is notable. As of now, he holds a significant number of stock options and restricted stock units (RSUs). In 2023, he was granted 14,775 RSUs, which are expected to vest over the next...

Brian J. Blaser's financial stake in QuidelOrtho is notable. As of now, he holds a significant number of stock options and restricted stock units (RSUs). In 2023, he was granted 14,775 RSUs, which are expected to vest over the next three years. This aligns his financial interests with the company's long-term growth, with a vested value of approximately $1.09 million. Previously, his holdings marked a high point when he transitioned to his current role, showing a strong commitment to the company's direction and vision. His holdings reflect a strategic approach where his wealth is tied directly to the performance of QuidelOrtho, emphasizing a true 'pay-for-performance' mentality.

Loading...

Insider Trading

See recent insider trades of Brian J. Blaser.

No insider trades found for this CEO.

Compensation History

See how much did Brian J. Blaser make over time.

In 2023, Brian J. Blaser received total compensation of about $3.32 million. This included a base salary of $621,000 and a performance-based bonus of $225,000, linked to achieving corporate goals like revenue and EBITDA targets. Also, he had vested stock worth approximately $1.09 million, a reflection of the company's ongoing initiatives in diagnostics. His bonus and equity compensation structure shows that he is motivated to steer the company towards greater profitability. The compensation plan is designed to attract high-quality executives and encourage them to align with shareholder interests, making Blaser's compensation a clear incentive for performance at QuidelOrtho.

Year

2023

Total Compensation

$1.96M

Salary

$621.00K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate high-quality executives, aligning their interests with those of stockholders through a pay-for-performance approach.

Bonus

$225.00K

Board Justification

The bonus is based on the achievement of corporate performance goals under the 2023 Cash Incentive Plan, which includes revenue and Adjusted EBITDA targets.

Other

$24.93K

Board Justification

Includes expense reimbursements and other personal benefits.

Restricted Stock

$1.09M(14.78K RSU)

Board Justification

The time-based RSUs granted in 2023 vest over a three-year period, with one-third vesting each year on the anniversary of the grant date.

Performance Metrics

The performance metrics for determining the compensation include revenue targets and Adjusted EBITDA targets.

Other QuidelOrtho Corporation CEOs

Here are other CEOs of QuidelOrtho Corporation

Michael S. Iskra

Ex-CEO of QuidelOrtho Corporation

February 2024 - May 2024